Literature DB >> 27076933

Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma.

Salvatore Conti1, Enzo Gallo1, Stefano Sioletic1, Francesco Facciolo1, Giovannella Palmieri1, Libero Lauriola1, Amelia Evoli1, Robert Martucci1, Anna Di Benedetto1, Flavia Novelli1, Diana Giannarelli1, Gloria Deriu1, Pierluigi Granone1, Margaret Ottaviano1, Paola Muti1, Edoardo Pescarmona1, Mirella Marino1.   

Abstract

BACKGROUND: The key role of egfr in thymoma pathogenesis has been questioned following the failure in identifying recurrent genetic alterations of egfr coding sequences and relevant egfr amplification rate. We investigated the role of the non-coding egfr CA simple sequence repeat 1 (CA-SSR-1) in a thymoma case series.
METHODS: We used sequencing and egfr-fluorescence in situ hybridization (FISH) to genotype 43 thymomas; (I) for polymorphisms and somatic loss of heterozygosity of the non-coding egfr CA-SSR-1 microsatellite and (II) for egfr gene copy number changes.
RESULTS: We found two prevalent CA-SSR-1 genotypes: a homozygous 16 CA repeat and a heterozygous genotype, bearing alleles with 16 and 20 CA repeats. The average combined allele length was correlated with tumor subtype: shorter sequences were significantly associated with the more aggressive WHO thymoma subtype group including B2/B3, B3 and B3/C histotypes. Four out of 29 informative cases analysed for somatic CA-SSR-1 loss of heterozygosity showed allelic imbalance (AI), 3/4 with loss of the longer allele. By egfr-FISH analysis, 9 out of 33 cases were FISH positive. Moreover, the two integrated techniques demonstrated that 3 out of 4 CA-SSR-1-AI positive cases with short allele relative prevalence showed significantly low or high chromosome 7 "polysomy"/increased gene copy number by egfr-FISH.
CONCLUSIONS: Our molecular and genetic and follow up data indicated that CA-SSR-1-allelic imbalance with short allele relative prevalence significantly correlated with EGFR 3+ immunohistochemical score, increased egfr Gene Copy Number, advanced stage and with relapsing/metastatic behaviour in thymomas.

Entities:  

Keywords:  Thymoma; allelic imbalance (AI); egfr microsatellite CA-SSR-1; egfr-fluorescent in situ hybridization (egfr-FISH); loss of heterozygosity; thymic epithelial tumors (TET)

Year:  2016        PMID: 27076933      PMCID: PMC4805790          DOI: 10.21037/jtd.2016.02.40

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  28 in total

1.  HER family receptor and ligand status in thymic carcinoma.

Authors:  Annikka Weissferdt; Heather Lin; Denise Woods; Ximing Tang; Junya Fujimoto; Ignacio I Wistuba; Cesar A Moran
Journal:  Lung Cancer       Date:  2012-06-20       Impact factor: 5.705

2.  Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression.

Authors:  H Buerger; F Gebhardt; H Schmidt; A Beckmann; K Hutmacher; R Simon; R Lelle; W Boecker; B Brandt
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas.

Authors:  T Mimae; K Tsuta; T Kondo; H Nitta; T M Grogan; M Okada; H Asamura; H Tsuda
Journal:  Ann Oncol       Date:  2012-06-13       Impact factor: 32.976

4.  Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.

Authors:  Seena C Aisner; Suzanne Dahlberg; Meera R Hameed; David S Ettinger; Joan H Schiller; David H Johnson; Joseph Aisner; Patrick J Loehrer
Journal:  J Thorac Oncol       Date:  2010-06       Impact factor: 15.609

5.  Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.

Authors:  Eriko Suzuki; Hidefumi Sasaki; Osamu Kawano; Katsuhiko Endo; Hiroshi Haneda; Haruhiro Yukiue; Yoshihiro Kobayashi; Motoki Yano; Yoshitaka Fujii
Journal:  Jpn J Clin Oncol       Date:  2006-06-08       Impact factor: 3.019

Review 6.  Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations--a link between genetics and epigenetics.

Authors:  F Gebhardt; H Bürger; B Brandt
Journal:  Histol Histopathol       Date:  2000-07       Impact factor: 2.303

7.  Cetuximab is an active treatment of metastatic and chemorefractory thymoma.

Authors:  Giovannella Palmieri; Mirella Marino; Marco Salvatore; Alfredo Budillon; Giuseppina Meo; Michele Caraglia; Liliana Montella
Journal:  Front Biosci       Date:  2007-01-01

8.  EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.

Authors:  Yogesh K Vashist; Florian Trump; Florian Gebauer; Asad Kutup; Cenap Güngör; Viacheslav Kalinin; Rather Muddasar; Eik Vettorazzi; Emre F Yekebas; Burkhard Brandt; Klaus Pantel; Jakob R Izbicki
Journal:  Target Oncol       Date:  2013-02-02       Impact factor: 4.493

9.  A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.

Authors:  Anthony Gonçalves; Séverine Esteyries; Brynn Taylor-Smedra; Arnaud Lagarde; Mounay Ayadi; Geneviève Monges; François Bertucci; Benjamin Esterni; Jean-Robert Delpero; Olivier Turrini; Bernard Lelong; Patrice Viens; Jean-Paul Borg; Daniel Birnbaum; Sylviane Olschwang; Frédéric Viret
Journal:  BMC Cancer       Date:  2008-06-10       Impact factor: 4.430

10.  Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer.

Authors:  Marcelo Sobral Leite; Letícia Carlos Giacomin; Diogo Nascimento Piranda; Juliana Simões Festa-Vasconcellos; Vanessa Indio-do-Brasil; Sérgio Koifman; Rodrigo Soares de Moura-Neto; Marcelo Alex de Carvalho; Rosane Vianna-Jorge
Journal:  BMC Cancer       Date:  2014-03-14       Impact factor: 4.430

View more
  1 in total

1.  Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.

Authors:  Teresa Bellissimo; Federica Ganci; Enzo Gallo; Andrea Sacconi; Claudia Tito; Luciana De Angelis; Claudio Pulito; Silvia Masciarelli; Daniele Diso; Marco Anile; Vincenzo Petrozza; Felice Giangaspero; Edoardo Pescarmona; Francesco Facciolo; Federico Venuta; Mirella Marino; Giovanni Blandino; Francesco Fazi
Journal:  Mol Cancer       Date:  2017-05-10       Impact factor: 27.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.